Clinical Trial Details

Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

IRB Protocol Number

Abbvie M18-868

Clinical Trial Categories

• Lung Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: Men or women, ages 18 and older, with locally advanced or metastatic non-squamous cell NSCLC with c-Met overexpression, who have received no more than 1 line of prior chemotherapy in the locally advanced or metastatic setting.